Create Anki flashcards covering the types of vasculitis, their pathophysiology, associated symptoms, complications, and treatment options.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vasculitis Anki Flashcards

Card 1: Classification by Vessel Size

Front: What are the three main categories of vasculitis based on vessel size?

Back:

  • Large vessel vasculitis: Giant cell arteritis (GCA), Takayasu arteritis (TAK)
  • Medium vessel vasculitis: Polyarteritis nodosa, Kawasaki disease
  • Small vessel vasculitis: ANCA-associated vasculitis (GPA, MPA, EGPA), IgA vasculitis (Henoch-Schönlein purpura), cryoglobulinemic vasculitis 1

Card 2: ANCA-Associated Vasculitis - Definition

Front: What are the three types of ANCA-associated vasculitis (AAV)?

Back:

  • Granulomatosis with polyangiitis (GPA) - formerly Wegener's
  • Microscopic polyangiitis (MPA)
  • Eosinophilic granulomatosis with polyangiitis (EGPA) - formerly Churg-Strauss 2, 3

Card 3: AAV Pathophysiology

Front: What is the pathophysiology of ANCA-associated vasculitis?

Back:

  • Autoantibodies: PR3-ANCA or MPO-ANCA target neutrophil antigens
  • Mechanism: Antibodies activate primed neutrophils causing degranulation and release of toxic oxygen radicals
  • Result: Necrotizing inflammation of small vessels (capillaries, venules, arterioles)
  • Tissue damage: Leads to glomerulonephritis, pulmonary hemorrhage, and systemic inflammation 2, 4

Card 4: AAV Organ-Threatening Manifestations

Front: What are examples of organ/life-threatening manifestations in AAV?

Back:

  • Glomerulonephritis
  • Pulmonary hemorrhage
  • Meningeal/CNS involvement
  • Retro-orbital disease
  • Cardiac involvement
  • Mesenteric involvement
  • Mononeuritis multiplex 2

Card 5: AAV Non-Organ-Threatening Manifestations

Front: What are examples of non-organ-threatening manifestations in AAV?

Back:

  • Nasal/paranasal disease without bony erosion
  • Skin involvement without ulceration
  • Skeletal myositis
  • Non-cavitating pulmonary nodules
  • Episcleritis 2

Card 6: AAV Diagnosis - ANCA Testing

Front: What is the recommended approach to ANCA testing in suspected AAV?

Back: Test for BOTH PR3-ANCA and MPO-ANCA using high-quality antigen-specific assays as the primary method (not immunofluorescence alone)

  • PR3-ANCA (cANCA): Highly specific for GPA, predicts prognosis
  • MPO-ANCA (pANCA): Associated with MPA, less specific
  • Biopsy strongly recommended to confirm diagnosis 2, 4

Card 7: AAV Treatment - Organ-Threatening Disease

Front: What is the recommended induction treatment for organ/life-threatening AAV?

Back: Glucocorticoids PLUS rituximab OR cyclophosphamide

  • Rituximab is preferred for relapsing disease
  • Glucocorticoid dosing: 50-75 mg prednisolone/day initially
  • Taper: Reduce to 5 mg/day by 4-5 months
  • Avacopan may be added to substantially reduce glucocorticoid exposure 2, 3

Card 8: AAV Treatment - Non-Organ-Threatening Disease

Front: What is the recommended treatment for non-organ-threatening AAV?

Back: Glucocorticoids plus rituximab

  • Alternatives to rituximab: Methotrexate or mycophenolate mofetil
  • Same glucocorticoid dosing and taper as organ-threatening disease 2

Card 9: AAV - Plasma Exchange Indication

Front: When should plasma exchange be considered in AAV?

Back: Consider for serum creatinine >300 µmol/L due to active glomerulonephritis

  • NOT routinely recommended for alveolar hemorrhage
  • Used in combination with standard immunosuppression 2

Card 10: AAV Complications

Front: What are major complications of AAV and its treatment?

Back: Disease complications:

  • End-stage renal disease
  • Permanent vision loss
  • Respiratory failure
  • Stroke/neurologic deficits

Treatment complications:

  • Infections (from immunosuppression)
  • Osteoporosis (from glucocorticoids)
  • Malignancy risk
  • Cumulative organ damage from drug toxicity 5, 6

Card 11: Giant Cell Arteritis - Key Symptoms

Front: What are the key symptoms of giant cell arteritis (GCA)?

Back:

  • New-onset persistent localized headache (often temporal)
  • Jaw/tongue claudication
  • Acute visual symptoms: Amaurosis fugax, diplopia, acute vision loss
  • Constitutional symptoms: Weight loss >2 kg, fever, fatigue
  • Polymyalgia rheumatica symptoms
  • Limb claudication 7

Card 12: GCA - Physical Examination Findings

Front: What are key physical examination findings in giant cell arteritis?

Back:

  • Temporal artery tenderness/thickening with reduced pulsation
  • Scalp tenderness
  • Bruits (particularly axillary)
  • Reduced pulses/blood pressure in upper limbs
  • Ophthalmologic findings: Anterior ischemic optic neuropathy, cranial nerve palsies, retinal artery occlusion 7

Card 13: GCA Pathophysiology

Front: What is the pathophysiology of giant cell arteritis?

Back:

  • Granulomatous inflammation of large and medium arteries
  • Primarily affects: Aorta and its major branches, especially extracranial carotid arteries
  • Histology: Multinucleated giant cells, fragmentation of internal elastic lamina
  • Result: Vessel wall thickening, luminal narrowing, ischemia of supplied territories 7, 1

Card 14: GCA Treatment

Front: What is the treatment for giant cell arteritis?

Back: Immediate high-dose glucocorticoids: 40-60 mg/day prednisolone

  • Start BEFORE diagnostic confirmation if visual symptoms present (strongest risk factor for blindness is treatment delay)
  • Taper: To 15-20 mg/day within 2-3 months, then ≤5 mg/day by 1 year
  • Fast-track referral: Within 24 hours to specialized center for imaging/biopsy 7

Card 15: GCA Complications

Front: What are the major complications of giant cell arteritis?

Back:

  • Permanent blindness (most feared, preventable with early treatment)
  • Stroke
  • Aortic aneurysm/dissection
  • Limb ischemia
  • Treatment-related: Glucocorticoid toxicity (osteoporosis, diabetes, infections) 7, 6

Card 16: Takayasu Arteritis - Key Symptoms

Front: What are the key symptoms of Takayasu arteritis?

Back:

  • New/worsening limb claudication
  • Constitutional symptoms: Weight loss >2 kg, fever, fatigue, night sweats
  • Myalgia, arthralgia, arthritis
  • Severe abdominal pain
  • Stroke, seizures (non-hypertensive), syncope, dizziness
  • Myocardial infarction, angina
  • Acute visual symptoms 7

Card 17: Takayasu Arteritis - Physical Findings

Front: What are key physical examination findings in Takayasu arteritis?

Back:

  • Hypertension (>140/90 mmHg)
  • Loss of pulses, pulse inequality
  • Bruits (over affected vessels)
  • Carotidynia (carotid artery tenderness)
  • Blood pressure discrepancies between limbs 7

Card 18: Takayasu Arteritis Pathophysiology

Front: What is the pathophysiology of Takayasu arteritis?

Back:

  • Granulomatous inflammation of large vessels
  • Primarily affects: Aorta and its major branches
  • Mechanism: T-cell mediated inflammation, giant cell infiltration
  • Result: Vessel wall thickening, stenosis, aneurysm formation, thrombosis
  • Demographics: Predominantly affects young women (<40 years) 7, 1

Card 19: Takayasu Arteritis Treatment

Front: What is the treatment for Takayasu arteritis?

Back: High-dose glucocorticoids: 40-60 mg/day prednisolone

  • Taper: To 15-20 mg/day within 2-3 months, then ≤10 mg/day by 1 year
  • Multidisciplinary management: Requires specialist team with imaging expertise
  • Additional immunosuppression often needed for refractory disease 7

Card 20: Takayasu Arteritis Complications

Front: What are major complications of Takayasu arteritis?

Back:

  • Aortic regurgitation
  • Aortic aneurysm/dissection
  • Renovascular hypertension
  • Stroke
  • Myocardial infarction
  • Limb ischemia requiring revascularization
  • Pulmonary hypertension 7, 6

Card 21: Polyarteritis Nodosa - Features

Front: What are the key features of polyarteritis nodosa (PAN)?

Back: Medium vessel necrotizing vasculitis WITHOUT glomerulonephritis or pulmonary involvement

  • Symptoms: Fever, weight loss, myalgia, peripheral neuropathy (mononeuritis multiplex), abdominal pain, testicular pain
  • Skin: Livedo reticularis, nodules, ulcers
  • Associated: Hepatitis B in some cases
  • ANCA-negative 1, 8

Card 22: Polyarteritis Nodosa Treatment

Front: What is the treatment for polyarteritis nodosa?

Back: Glucocorticoids improve prognosis

  • Systemic PAN: Glucocorticoids + cyclophosphamide for severe disease
  • Cutaneous PAN: Colchicine or dapsone
  • Hepatitis B-associated: Antiviral therapy + short-course steroids, consider plasma exchange 8

Card 23: IgA Vasculitis (Henoch-Schönlein Purpura)

Front: What are the key features of IgA vasculitis (Henoch-Schönlein purpura)?

Back: Small vessel vasculitis with IgA immune complex deposition

  • Classic tetrad: Palpable purpura (lower extremities/buttocks), arthralgia, abdominal pain, glomerulonephritis
  • Pathophysiology: IgA-containing immune complexes deposit in vessel walls
  • More common in children
  • Diagnosis: Skin/renal biopsy shows IgA deposition 8, 4

Card 24: IgA Vasculitis Treatment

Front: What is the treatment for IgA vasculitis (Henoch-Schönlein purpura)?

Back: Most cases self-limited, symptomatic treatment sufficient

  • Mild disease: NSAIDs for arthralgia, supportive care
  • Severe glomerulonephritis in adults: Insufficient evidence for glucocorticoids, use ACE inhibitors based on symptoms
  • Hemorrhagic skin lesions suggesting necrosis: Consider glucocorticoids 8

Card 25: Leukocytoclastic Vasculitis

Front: What are the features and treatment of leukocytoclastic vasculitis?

Back: Small vessel vasculitis with neutrophil infiltration and nuclear debris

  • Causes: Drugs, infections, connective tissue diseases, malignancy
  • Presentation: Palpable purpura, typically lower extremities
  • Pathology: IgG or IgM immune complexes (better prognosis than IgA)
  • Treatment: Remove trigger if identified; for chronic/relapsing disease use colchicine or dapsone; glucocorticoids if skin necrosis threatens 8, 4

Card 26: Cryoglobulinemic Vasculitis

Front: What are the features and treatment of cryoglobulinemic vasculitis?

Back: Small vessel vasculitis from cryoglobulin immune complex deposition

  • Triad: Palpable purpura, arthralgia, weakness
  • Associated: Hepatitis C (most common), lymphoproliferative disorders
  • Lab: Low C4, positive cryoglobulins, positive rheumatoid factor
  • Treatment: Treat underlying disease (antivirals for HCV, treat lymphoma/myeloma); plasma exchange for severe cases 8, 4

Card 27: Urticarial Vasculitis

Front: What distinguishes urticarial vasculitis from ordinary urticaria?

Back: Urticarial lesions that last >24 hours and leave residual hyperpigmentation

  • Pathophysiology: Small vessel vasculitis with immune complex deposition
  • Symptoms: Painful/burning urticarial lesions (vs. pruritic in ordinary urticaria)
  • May have: Arthralgia, low complement (hypocomplementemic urticarial vasculitis syndrome)
  • Treatment: Dapsone or colchicine usually first-line 8

Card 28: AAV Prophylaxis and Monitoring

Front: What prophylaxis and monitoring is recommended for patients with AAV on treatment?

Back: Mandatory prophylaxis:

  • PCP prophylaxis (trimethoprim-sulfamethoxazole) during intensive immunosuppression
  • Osteoporosis prevention: Calcium, vitamin D, bisphosphonates
  • Lifestyle advice: Smoking cessation, infection prevention

Periodic screening for:

  • Treatment-related infections
  • Malignancy
  • Cardiovascular disease
  • Bone health 2

Card 29: AAV Multidisciplinary Management

Front: Why is multidisciplinary management essential in AAV?

Back: AAV is rare, heterogeneous, and potentially life/organ-threatening

Requires expertise in:

  • Rheumatology (primary management)
  • Nephrology (renal involvement)
  • Pulmonology (lung involvement)
  • ENT (upper airway disease)
  • Ophthalmology (ocular complications)
  • Neurology (peripheral/CNS involvement)

Patients should be managed at or have access to specialized vasculitis centers 2, 3


Card 30: Vasculitis - General Diagnostic Approach

Front: What is the essential diagnostic approach for suspected vasculitis?

Back: Biopsy is nearly always essential for diagnosis (except Takayasu arteritis where aortography is indicated)

Key steps:

  1. Detailed history: Onset, course, organ systems affected
  2. Physical examination: Assess extent of involvement
  3. Laboratory tests: ANCA, inflammatory markers (ESR/CRP), complement, cryoglobulins
  4. Imaging: Based on suspected vessel size (ultrasound, CT angiography, MR angiography, PET-CT)
  5. Tissue biopsy: From involved organ when feasible 1, 6

References

Research

Vasculitis: diagnosis and therapy.

The American journal of medicine, 1996

Research

Vasculitis.

The Journal of dermatology, 1995

Research

An Update on Vasculitis for the General Physician.

British journal of hospital medicine (London, England : 2005), 2025

Research

[Therapy of vasculitides and vasculopathies].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2008

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.